# case_09_node_2

## Outcome

- Recovered run status: `degraded`; final source: LLM.
- Target: rechallenge with reduced camrelizumab+pemetrexed+carboplatin after prior grade-IV leukopenia/neutropenia in KRAS G12V metastatic lung adenocarcinoma with brain metastasis.
- The final answer predicted limited benefit/stability, low confidence, PR-like CNS control and grade-3 marrow toxicity with dose modification. It cited two cutoff-valid case records but explicitly stated that direct target-regimen evidence was absent.

## Component audit

- Context was conservative: it kept `key_findings=[]`, listed the direct-evidence and rechallenge safety gaps, and did not claim that the analog regimen was direct evidence.
- The final answer still used two analogous pembrolizumab/carboplatin/pemetrexed cases as supporting context. This is acceptable only as clearly labelled class-level analogy, not as evidence for camrelizumab or the patient's prior grade-IV toxicity.
- Reranking had four API attempts with three errors; Evidence Review and Safety Reflection both timed out and used fallback outputs. The run is therefore correctly marked `degraded`, not complete.
- The recovery demonstrates the protocol issue is intermittent/latency-sensitive rather than a permanent QueryUnderstanding failure. It also shows that fallback-stage metadata is necessary for interpreting benchmark scores.

## Classification

- General clinical issue: class-level analogs must remain separated from exact-drug and rechallenge evidence.
- General reliability issue: timeout/fallback stages can still yield a coherent answer, but must remain visible in `failed_stages` and must not count as a fully successful trajectory.
- Positive behavior: the Context and final rationale preserved the prior grade-IV toxicity as a patient-specific risk instead of treating generic class safety as proof of safety.
